Advance Online
A multiracial group of friends sitting at a dinner table with food and drinks, smiling at the camera.
Advance Online

FDA Approves VTAMA® for Adults with Psoriasis

A new non-steroidal topical medication option is coming to the market.

On May 24, 2022, the U.S. Food and Drug Administration (FDA) approved VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. VTAMA® cream is the first and only FDA-approved steroid-free topical medication in its class. [1]

This approval is based on findings from PSOARING 1, 2, and 3, with PSOARING 3 being a long-term extension study. During Phase 3 LTE, over 40% of study patients achieved complete disease clearance (PGA=0) at least once during the study period. [1]

“Tapinarof is a novel non-steroidal topical cream approved for psoriasis. It offers once-daily application and a high chance of clearance of the localized psoriasis. Some patients (about 20%) will experience a folliculitis of the skin at the treatment areas, but very few (<2% in the studies) will stop treatment due to this relatively mild side effect. Finally, some patients who clear with the use of tapinarof will note a long period of time that the psoriasis remains clear while not using the medication (remission) before having to use the cream again,” shared Bruce Strober, M.D., Ph.D., a Clinical Professor in the department of dermatology at Yale University School of Medicine, New Haven, Connecticut, and a board certified dermatologist at Central Connecticut Dermatology Research, Cromwell, Connecticut.

Furthermore, data from the Phase 3 LTE study showed consistent and positive patient satisfaction. [1]

Treatments

Learn more about your treatment options for psoriatic disease, including non-steroidal topicals.

Explore treatments

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.